Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.54 |
| ▸ | TSHR | P16473 | 7/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19693711 | 0.84 | CYP2D6 (0.50) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 | |
| SCHEMBL4692167 | 0.78 | CYP2D6 (0.70) | CYP2D6CYP3A4TSHRCHRM2CHRM3 | |
| SCHEMBL5243003 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 | |
| SCHEMBL1732446 | 0.76 | CYP2D6 (0.65) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 | |
| SCHEMBL25685294 | 0.75 | SIGMAR1 (0.58) | CYP2D6CYP3A4TSHR | |
| SCHEMBL6621788 | 0.75 | CYP2D6 (0.56) | CYP2D6CYP3A4TSHRCHRM2CHRM3 | |
| SCHEMBL484644 | 0.75 | SIGMAR1 (0.56) | CYP2D6CYP3A4TSHRCYP1A2CYP2C9 | |
| SCHEMBL2381838 | 0.75 | CYP2D6 (0.67) | CYP2D6CYP3A4TSHRCHRM2CHRM3 | |
| SCHEMBL24994297 | 0.74 | CYP2D6 (0.55) | CYP2D6CYP3A4TSHRCHRM2CHRM3 | |
| SCHEMBL23968815 | 0.74 | CYP2D6 (0.87) | CYP2D6CYP3A4TSHRCHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3468966-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2019-05-16 | — | — | US | disclosed |
| EP-3468966-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885CYP3A4 4408/4885TSHR 4567/4885 |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885CYP3A4 4408/4885TSHR 4567/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885CYP3A4 4408/4885TSHR 4567/4885 |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885CYP3A4 4408/4885TSHR 4567/4885 |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2D6 4548/4885CYP3A4 4408/4885TSHR 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.